Previously writing on company which describes itself as “a leading developer and manufacturer of lithium-ion and sodium-ion battery cells for specialist markets”, in July with the shares down to 4.25p I noted it’s good luck with a sustainable financial solution within the next few business days and it remains that hopefully our prior warnings were heeded, bargepole/sell. The shares had since risen to above 9p as financial hopes were raised and now the company “is pleased to announce” that it has conditionally placed new shares to raise approximately £2.1 million and is proposing to raise up to a further £0.25 million in a “retail offer” via the Bookbuild platform. So what of a share price currently down to 2.15p?!

Just under three months ago, I observed that “Halfords (HFD) is keeping its motor running for me (as an investor)”. That was a pretty sad reference to late 1960s music, but I am sure a bunch of you know that the company takes its name from Halford Street in Leicester where it was founded in 1892. Just a bit more relevant for today is how its 2020s progress is getting on, which brings us to Wednesday’s twenty-week trading update.

We tipped shares in Restore plc (RST) as a recovery Buy on 18th August at a 142p offer price, considering that the valuation following prior trading disappointment meant that a 190p share price looked realistic on just the company showing it delivering on the expectations from there. The potential value was already being realised somewhat by the market as the shares recently closed at 180p… and now a “Significant Contract Win” announcement.

Previously writing on UK building materials distributor Lords Group Trading (LORD), in June with the shares up to 61.5p I concluded that I then avoided as I questioned whether consumer demand had been fully impacted yet. The shares had risen to mostly recently close at 68.5p but what of half-year results today currently seeing them back towards 60p?

Previously writing on Polarean Imaging (POLX), a medical imaging company which emphasises it has “developed the first and only hyperpolarised MRI contrast agent to be approved in the United States”, in February with the shares falling below 40p I concluded that the valuation and financial outlook in a still-challenging funding environment meant I certainly avoided. The shares most recently closed at 14.5p, and what of they currently at 11.5p on the back of half-year results?

I don’t need a new computer at the moment but when I buy my next one I am pretty sure that I will use Currys (CURY). A couple of months ago, I shared why I thought it was smart to copy the move of Fraser Group (FRAS) and buy shares in Currys at the then just below 50p level. How is that getting along?